Comparative Effectiveness Research in Action



Case study 1: Lucentis vs. Avastin

- Similar molecules made by the same company, but with different indications and cost
- Difficulty in performing a head-to-head trial
- 1st year CATT results published in NEJM
 - Equivalent visual outcomes
 - 24% vs. 19% serious systemic adverse advents in disease categories not identified in previous studies as areas of concern
- Industry-funded observational analysis of Medicare data showed higher rates of side effects
- VA halts Avastin use
- Manufacturer position
- American Academy of Ophthalmology position



Questions raised

- Is Lucentis vs. Avastin a good example of a high priority for patient-centered outcomes research?
 - Is it politically sustainable?
- In the future would PCORI or NEI fund this?
- What would PCORI's dissemination effort consist of?



The NEW ENGLAND JOURNAL of MEDICINE



Bevacizumab versus Ranibizumab for AMD Philip J. Rosenfeld, M.D., Ph.D.

with the choice between two drugs for the treat- level I evidence.6 ment of neovascular age-related macular degeneration (AMD), a common cause of irreversible blindness among the elderly worldwide. Vision loss from the first year of the Comparison of AMD results from the abnormal growth and leakage of Treatment Trials (CATT), a large, prospective, blood vessels in the macula, a specialized portion of the retina responsible for the best visual acuity. Without this macular vision, patients become legally blind. Vascular endothelial growth pared the two drugs and two different dosing

factor (VEGF), the cytokine primarily responsible and blindness is prevented in most patients. The improvement in vision.1-3

The two anti-VEGF drugs most commonly (Lucentis), both developed by Genentech.4 Bevacizumab, a full-length humanized monoclonal antibody, has been approved by the Food and Drug Administration (FDA) for the systemic treat- the injection of ranibizumab or bevacizumab. An ment of certain cancers. Ranibizumab, an antigen- OCT-guided as-needed regimen has been shown diseases and is derived from the same anti-VEGF a monthly regimen with an as-needed regimen. mouse monoclonal antibody as bevacizumab.

For 5 years, patients and clinicians have wrestled widespread use of bevacizumab in the absence of

In this issue of the Journal, Martin and colleagues7 provide such evidence in their findings multicenter, randomized clinical trial comparing bevacizumab and ranibizumab. Despite formidable obstacles,8 the investigators successfully comregimens: a monthly regimen versus an as-needed for blood-vessel growth, is inhibited when anti- regimen (i.e., drug administration only when signs VEGF drugs are injected repeatedly into the eye, of exudation are present). A monthly regimen is considered the standard for treatment.1,2 An asmajority of treated patients go on to have some needed regimen is used less frequently and relies on clinical judgment and imaging techniques to determine when to reinject the drug.9 The most used are bevacizumab (Avastin) and ranibizumab common imaging method that is used is optical coherence tomography (OCT), a noninvasive technique that identifies fluid leakage from blood vessels. This VEGF-mediated exudate resolves after

binding fragment, is a smaller molecule that was to result in improved visual acuity,9 but CATT is specifically developed and approved to treat eve the first prospective approach to directly compare

Martin et al. found that the monthly use of Both ranibizumab and bevacizumab bind VEGF at either bevacizumab or ranibizumab results in the the same position; however, they differ in size, same visual acuity outcome. This finding holds affinity for VEGF, speed of clearance from the eye, true for the mean visual acuity and the proporand cost.5 Ranibizumab, the FDA-approved treat- tion of patients who gain 15 letters (which reprement for neovascular AMD, costs approximately sents a doubling of the visual acuity), lose 15 let-\$2,000 per dose, whereas bevacizumab, the off-ters, or remain stable. Critics will argue that the label treatment, costs approximately \$50. This cost OCT outcomes suggest differences between these difference, along with the perceived clinical simi- two drugs. Although the OCT retinal thickness larities between these two drugs, has led to the measurements favor ranibizumab, this difference



1966

N ENGL J MED 364;20 NEJM.ORG MAY 19, 2011

The New England Journal of Medicine Downloaded from nejm.org at NIH on September 21, 2011. For personal use only. No other uses without permission. Copyright © 2011 Massachusetts Medical Society. All rights reserved.

Case study 2: Metal-on-metal hips

- 500,000 patients in the US
- Some researchers warned of potential health threats of metal debris
- UK national registry:
 - 14% of patients needed joint removed or replaced after 7 years vs. 3% for other types of hips
- 2010 FDA recall of J&J version: UK registry showed 30% needed early replacement
- May 2011 FDA orders all makers of metal-on-metal hips to develop studies to track negative outcomes
- First six months of 2011 more than 5,000 reports of "problems" with all-metal hips, many patients getting blood tests and diagnostic scans



Questions raised


- Is this an example of regulatory failure?
- Would funding infrastructure for a US registry akin to the UK be a top priority for PCORI?
- How would PCORI coordinate with FDA in post-market surveillance of new devices?



Case study 3: "Real-world" CER

- "Even after PCORI is up and running, insurers will be left to their own devices."
 - Wellpoint and others using their own data to perform CER
 - Captures adherence and ancillary utilization
- Yale-Medtronic YODA project
- New England Comparative Effectiveness
 Public Advisory Council (CEPAC)





The New England Comparative Effectiveness Public Advisory Council

Case study 3: "Real-world" CER

- New England Comparative Effectiveness
 Public Advisory Council (CEPAC)
 - Supplements AHRQ reviews with state utilization patterns, budget impact, cost-effectiveness, PMPM, implicit trade-offs
 - Votes and recommendations of CEPAC to support payer and provider policies



Questions raised

- What relationship should PCORI seek with insurer CER efforts?
- Is an open data access model for CER research good for everyone?
- How will PCORI products be used at the local level to guide policy and practice?



Conclusions

- CER continues to cast a growing shadow in health care policy
- While PCORI will be a major force, it is clear that the reverberations of CER are being felt across all health care sectors and CER will be led by many rather than few
- One of the many remaining questions:
 - What are the outcomes by which the comparative effectiveness of PCORI and CER will ultimately be judged?

